Q4 report due on Thursday, 16 February Sale of Centennial Flats expected to be the main EBIT driver ...
Redeye comments on the newly released terms and conditions for the ongoing capital raise, including ...
Redeye updates its view on the lawsuit with a new schedule and an updated view on the number of unit...
Botten var i Q3 – vi väntar oss en successiv förbättring framöver I linje med vad som kommunicerats ...
Redeye leaves a comment on Faron Pharmaceutical's recent private placement.
Consti reports its Q4 2022 results on February 3rd.
Redeye is pleased to note that Lifeclean did a direct issue of SEK 27m after costs this morning.
Q4 report due on Thursday, 23 February Updated outlook following recent change of analyst Trading at...
Cons. expects FY'22 org growth of 3.8% vs. guidance of 4-6% China reopening likely not a major cons.
Q4 hit by US snowstorms and one-off items Probi reported a weak quarter again, with -27% organic gro...
Svagt kvartal, utdelning bör ge stöd till aktien BE Group rapporterade en underliggande Q4’22 EBIT p...
SEK 40m Intercom order from existing EU customer Strong order intake, ATH backlog & margin expansion...
Suominen reports Q4 results on Feb 3. It’s clear Q4 will be a lot better than previous quarters, whi...
Analyst Group har med Blick Global Group ingått avtal om kontinuerlig analysbevakning, innefattande ...
Fair value range of SEK 9-18 (9-21) Q4e: strong Freemelt ONE sales and an insurance one-off For Q4e,...
Redeye updates its estimates following Beijer Group’s Q4 2022 report.
Efterfrågan är gynnsam på samtliga marknader utom Kina Den organiska tillväxten i orderingången var ...
EBITDA SEK -1m vs. ABGSCe SEK 0m Launched a cost savings programme Conference call at 11.
VEF took a defensive stance in 2022, focusing on strengthening its balance sheet and reprioritising ...
Redeye retains its positive view of Formpipe following robust preliminary Q4 figures.
